提供学术论文选刊润色服务
医学
医学
Paper Review Records
全部论文审稿周期
10 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
240
天
Optimizing Drug-Resistant Epilepsy Management: Cenobamate’s role in the Surgery/Neuromodulation Pathway
作者Giancarlo Di Gennaro; Paolo Bonanni; Francesco Deleo; Antonio Gambardella; Roberto Michelucci; Giada Pauletto; Nicola Specchio; Alfredo D’Aniello
作者单位1. IRCCS NEUROMED, Pozzilli, Italy; 2. IRCCS E. Medea Scientific Institute, Epilepsy Unit, Conegliano, Italy; 3. Epilepsy Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; 4. Azienda Ospedaliero-Universitaria “Renato Dulbecco” di Catanzaro, Catanzaro, Italy; 5. IRCCS-Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; 6. SOC Neurologia, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy; 7. Neurology, Epilepsy and Movement Disorders Unit, Bambino Gesu’ Children’s Hospital, IRCCS, Full Member of European Reference Network on Rare and Complex Epilepsies, EpiCARE, Rome, Italy; 8. University Hospitals, KU Leuven, Leuven, Belgium
71
天
Gabapentin Extended Release Tablets in Healthy Subjects Under Fed Conditions: A Randomized, Open-Label, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Comparative Bioavailability Study
作者Sudershan Kumar; Arshad Khuroo; Sanjay Jagannath Gurule; Sachin Mehra; Hari Krishan Tiwari; Y. Zala; Venkata Rama Rao Kamala; Madhu Kandukuri; Shruti Dharmadhikari; Prashant Devkare; Chintan Khandhedia
作者单位1. Clinical Pharmacology and Pharmacokinetics, Sun Pharmaceutical Industries Limited, Gurgaon, India; 2. Clinical Pharmacology Unit, Sun Pharmaceutical Industries Limited, Gurgaon, India; 3. Formulation Department, Sun Pharma Advanced Research Company (SPARC) Ltd, Mumbai, India; 4. Medical Affairs and Clinical Research, Sun Pharma Laboratories Limited, Mumbai, India; 5. Medical Affairs and Clinical Research, Sun Pharmaceutical Industries Limited, Mumbai, India
148
天
Development and Optimization of a Biphasic-Release Acetazolamide Tablet-in-Tablet Formulation
作者Si-kai Wang; Wei Li; Miao-miao Guo; Man Han; Ze-chun Long; Jin-hui He; Xiang-yang Xie; Yuan Zeng; Hui Liu
作者单位1. School of Pharmacy, Hubei University of Chinese Medicine, Wuhan, China; 2. Department of Clinical Pharmacy, General Hospital of Central Theater Command, Wuhan, China; 3. Department of Pharmacy, Jingmen People’s Hospital, Jingmen, China; 4. School of Pharmaceutical Sciences, Hubei University of Medicine, Shiyan, China; 5. School of Pharmacy, Hubei University of Science and Technology, Xianning, China; 6. College of Nursing and Health Management and College of Life Science and Chemistry, Wuhan Donghu University, Wuhan, China; 7. Department of Pharmacy, General Hospital of Central Theater Command, Wuhan, China
135
天
A Combination of the Tryptophan Hydroxylase Inhibitor Telotristat with the mTOR Inhibitor Everolimus as an Effective Strategy Against Neuroendocrine Tumors
作者Javier Molina-Cerrillo; Arantzazu Sierra-Ramirez; José L. López-Aceituno; Marinela Méndez-Pertuz; Teresa Alonso-Gordoa; Michael Linnebacher; Matteo Santoni; Pablo J. Fernandez-Marcos; Enrique Grande
作者单位1. Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain; 2. Metabolic Syndrome Group-BIOPROMET, Madrid Institute for Advanced Studies-IMDEA Food, CEI UAM+CSIC, Madrid, Spain; 3. CNIO Cancer Center, Madrid, Spain; 4. Department of General Surgery, Section of Molecular Oncology and Immunotherapy, University of Rostock, Rostock, Germany; 5. Medical Oncology Unit, Macerata Hospital, Macerata, Italy; 6. Medical Oncology Department, MD Anderson Cancer Center Madrid, Madrid, Spain
228
天
138
天
Updated Viloxazine Pharmacology: Experiments Establish Norepinephrine Transporter Occupancy and Serotonin 5-HT 2C , 5-HT 2B , and 5-HT 7 Receptor Binding at Therapeutically Relevant Concentrations
作者Jennie Garcia-Olivares; Brittney Yegla; Jennifer Koch; Chungping Yu; Jonathan Rubin
作者单位1. Supernus Pharmaceuticals, Inc., Rockville, USA
222
天
Arylpiperazine Derivative NAF19 Inhibits Prostate Cancer Activity and Its Molecular Mechanisms
作者Hua Jiang; Mingzhen Xu; Songsong Jiang; Weiqiang Huang
作者单位1. Department of Urology, The Fifth Affiliated Hospital of Zunyi Medical University (Zhuhai Sixth People’s Hospital), Zhuhai, China; 2. The Department of Biological and Pharmaceutical Sciences, Zhuhai Campus of Zunyi Medical University, Zhuhai, China
100
天
Treatment Outcomes with Lanadelumab Every 2 Weeks and Garadacimab are Very Similar in Patients with Hereditary Angioedema
作者Irmgard Andresen; Natalie Khutoryansky; Sarah L. Feeny; Alissa Dangel
作者单位1. Takeda Pharmaceuticals International AG, Zurich, Switzerland; 2. Takeda Development Center Americas, Inc., Lexington, USA; 3. Takeda Pharmaceuticals USA, Inc., Cambridge, USA
314
天
The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies
作者HeeJae Choi; Shilpa Madari; Elmar Daalman; Brett A. English; Atef Halabi; Kathrin Hohl; Yury Shatillo; Nathalie Weidinger; Michael Desch
作者单位1. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, USA; 2. Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany; 3. CRS Clinical Research Services Kiel GmbH, Kiel, Germany
187
天
Advanced Drug Delivery Strategies for Overcoming Biological Barriers: Tumor Microenvironment and Blood–Brain Barrier
作者Yicong Lei; Tingyu Xiao; Xin Hu; Huaqing Lin
作者单位1. Key laboratory for Advanced Drug Delivery Systems of Guangdong Province, Guangdong Pharmaceutical University, Guangzhou, People’s Republic of China
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿96.4 天
中位数77 天